|
Fuji Pharma Co., Ltd. is a pharmaceutical company focused on the development, manufacturing, and sales of injectable medications. The company operates a single business segment comprising therapeutic and diagnostic drugs. Its product portfolio is centered on hormonal agents for obstetrics and gynecology and contrast media for radiology, specifically for urinary and vascular imaging. Fuji Pharma serves the Japanese market through a network of five offices and maintains a subsidiary relationship with OLIC (Thailand) Limited for product trading and financial transactions. The company is currently developing new indications and dosage forms for existing hormonal agents, sustained-release formulations, and biogeneric drugs utilizing recombinant technology. Summarised from the annual report, fiscal year ended Sep 2025 |
Industry Drug Manufacturers - Specialty & Generic | Homepage fujipharma.jp |
| Sector Healthcare | IR page fujipharma.jp | |
|
Tags
hormonal agents, contrast media, obstetrics, gynecology, radiology, biogenerics, sustained-release formulations, injectable medications, OLIC (Thailand) Limited
|
Press page fujipharma.jp/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 46.845B |
| Market cap (USD) | $ 292.785M |
| P/E | 15.88 |
| PEG | — |
| P/BV | 0.89 |
| P/S | 0.75 |
| P/OCF | 7.59 |
| P/FCF | 24.06 |
| Dividend yield | 2.9% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 5.7% |
| ROI | 5.4% |
| ROIC | 9.1% |
| Profit margin | 4.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | -6.2% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 11 |
| Quality score | 22.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.386B | 51.677B | 46.138B | 40.889B | 35.426B | 33.99B | 33.793B | 36.279B | 37.909B | 35.387B | 34.229B | 31.68B | 29.215B | 25.174B | 21.52B |
| Net profit | 2.831B | 3B | 6.146B | 3.435B | 2.696B | 2.432B | 2.085B | 2.962B | 3.372B | 3.301B | 2.118B | 2.092B | 2.078B | 2.068B | 1.37B |
| Free cash flow | — | 1.947B | -221M | -1.98B | -13.081B | 2.097B | 3.155B | 3.751B | 2.143B | 1.696B | 1.855B | -954M | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 1.765K | 1.546K | 1.273K | 1.166K | 1.034K | 1.17K | 1.249K | 1.317K | 1.792K | 3.839K | 2.681K | 2.002K | 2.031K | 1.737K | 1.286K |
| Price performance 12m | 0.14 | 0.21 | 0.09 | 0.13 | -0.12 | -0.06 | -0.05 | -0.26 | -0.53 | 0.43 | 0.34 | -0.01 | 0.17 | 0.35 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 15.1B | 16.9B | 12.9B | 11.7B | 11.9B | 12.5B | 16.3B | 18.4B | 18B | 20.5B |
| ↳ YoY growth | +15.8% | +11.6% | -23.4% | -9.6% | +1.4% | +5.6% | +30.2% | +13.0% | -2.4% | +14.1% |
| ↳ 5y CAGR | -1.1% | -1.9% | -3.7% | -0.7% | +7.3% | +9.0% | +11.6% | |||
| Other receivables (JPY) | 20M | 39M | 43M | 8M | 118M | 134M | 216M | 453M | 296M | 454M |
| Borrowings, current (JPY) | 653M | — | 2.84B | 2.64B | 8.84B | 10.7B | 16.5B | 22.4B | 17.3B | 17.2B |
| Borrowings, non-current (JPY) | 2B | 2B | 5.53B | 7.59B | 6.63B | 11.2B | 8.68B | 1.58B | 8.95B | 7.05B |
| Bonds payable (JPY) | — | — | — | — | — | — | 2.7B | 2.1B | 2.45B | 1.75B |
| Lease liabilities (JPY) | 2.21B | 3.07B | 2.54B | 1.96B | 3.19B | 2.64B | 3.76B | 5.27B | 4.7B | 4.12B |
| Cash and deposits (JPY) | 5.5B | 6.25B | 8.49B | 12B | 10.2B | 3.55B | 2.32B | 4.59B | 7.25B | 9.5B |
| Intangible assets (JPY) | 2.71B | 2.22B | 3.3B | 2.9B | 2.4B | 10.4B | 10.5B | 12.4B | 13.9B | 13.7B |
| Net debt (borrowings + leases - cash) (JPY) | -638M | -1.18B | 2.42B | 149M | 8.46B | 21B | 26.6B | 24.7B | 23.7B | 18.9B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 3.24B | 3.77B | 7.04B | 5.77B | 5.99B | -658M | 1.92B | 4.15B | 5.8B | 6.17B |
| Purchases of property, plant and equipment (JPY) | -1.48B | -1.45B | -1.7B | -2.32B | -3.79B | -5.1B | -3.33B | -2.78B | -1.98B | -2.09B |
| Purchases of intangible assets (JPY) | -65M | -184M | -1.58B | -293M | -107M | -7.33B | -570M | -1.59B | -1.87B | -1.81B |
| Change in receivables (cash effect) (JPY) | -1.98B | -1.73B | 3.97B | 1.2B | -174M | -549M | -3.71B | -2B | 525M | -2.53B |
| Change in inventories (cash effect) (JPY) | 185M | 235M | 581M | -23M | -1.34B | -3.62B | -3.4B | 1.55B | -3.08B | -1.29B |
| Change in payables (cash effect) (JPY) | -642M | 994M | -1.94B | -1.1B | 2.04B | 447M | -652M | -1.64B | 356M | -895M |
| Dividends paid (cash effect) (JPY) | -704M | -794M | -839M | -904M | -807M | -729M | -899M | -972M | -1.04B | -1.23B |
| Share buybacks (cash effect) (JPY) | 0.00 | -40M | 0.00 | 0.00 | -9.41B | — | — | — | — | — |
| Interest paid (cash effect) (JPY) | -45M | -70M | -53M | -41M | -59M | -82M | -104M | -194M | -327M | -393M |
| Income taxes paid (cash effect) (JPY) | -1.09B | -1.8B | -957M | -723M | -911M | -1.5B | -946M | -1.03B | -2.2B | -1.76B |
| Operating cash flow before change in receivables (JPY) | 5.22B | 5.5B | 3.07B | 4.57B | 6.17B | -109M | 5.62B | 6.15B | 5.28B | 8.7B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 1.7B | 2.14B | 3.75B | 3.16B | 2.1B | -13.1B | -1.98B | -221M | 1.95B | 2.28B |
| Income detail | ||||||||||
| Research and development expense (JPY) | 1.83B | 1.76B | 2.05B | 3.06B | 2.45B | 2.49B | 3.18B | 3.4B | 3.34B | 4.06B |
| ↳ 5y CAGR | +12.1% | +5.9% | +6.4% | +12.6% | +10.6% | +1.8% | +10.7% | |||
| Total comprehensive income (JPY) | 4.07B | 3.57B | 2.61B | 1.49B | 2.9B | 3.89B | 6.26B | 5.29B | 2.17B | 3.45B |
| Comprehensive income to owners (JPY) | 4.07B | 3.57B | 2.61B | 1.49B | 2.9B | 3.89B | 6.26B | 5.29B | 2.17B | 3.45B |
| Reported | Dec 20, 2017 | Dec 19, 2018 | Dec 19, 2019 | Dec 18, 2020 | Dec 20, 2021 | Dec 21, 2022 | Dec 21, 2023 | Dec 23, 2024 | Dec 18, 2025 | Nov 10, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Fuji Pharma Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DISV | 0.03% | 131,499 | $ 1.544M | Nov 12, 2026 |
| AVDV | 0.02% | 251,700 | $ 2.932M | Nov 16, 2026 |
| AVDS | 0.01% | 2,300 | $ 26.795K | Nov 16, 2026 |
| DXIV | 0.01% | 1,800 | $ 21.141K | Nov 12, 2026 |
| DFIS | 0.01% | 32,400 | $ 380.533K | Nov 12, 2026 |
| DFIC | 0.00% | 29,000 | $ 340.6K | Nov 12, 2026 |
| DFAX | 0.00% | 16,700 | $ 196.139K | Nov 12, 2026 |
| DFAI | 0.00% | 21,100 | $ 247.816K | Nov 12, 2026 |
| AVDE | 0.00% | 20,500 | $ 238.826K | Nov 16, 2026 |

